CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis
Authors Zhang Y, Xu L, Peng M
Received 18 November 2017
Accepted for publication 16 January 2018
Published 27 February 2018 Volume 2018:11 Pages 1045—1054
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Ingrid Espinoza
Yang Zhang,1 Linjuan Xu,2 Minggang Peng2
1Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Objective: To deeply verify the clinical significance of CXCR3 in prediction of cancer patients’ prognosis.
Data sources: We performed a meta-analysis including 12 studies searched from PubMed, Web of Science, Embase, and Cochrane databases. A total of 1,751 patients were used to analyze the association between CXCR3 and patients’ prognosis, based on either overall survival or time to tumor progression.
Study selection: Studies evaluating CXCR3 expression for predicting prognosis in human solid tumors were included.
Results: It showed that patients with higher expression of CXCR3 had significantly shorter OS (pooled hazard ratio =2.315, 95% CI: 1.162–4.611, P=0.017). In addition, higher CXCR3 expression was associated with distant metastasis (yes vs no: pooled relative ratio [RR] =1.828, 95% CI: 1.140–2.931, P=0.012) in solid tumors and indicated advanced tumor stage (III/IV vs I/II, RR =2.656, 95% CI: 1.809–3.900, P<0.001) and lymph node metastasis (yes vs no: RR =2.28, 95% CI: 1.61–3.25, P<0.001) in colorectal cancer.
Conclusion: Our study highlights the role of CXCR3 as a potential prognostic marker and a promising therapeutic target in solid tumors.
Keywords: CXCR3, meta-analysis, solid tumor, prognostic marker, overall survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]